Trials / Unknown
UnknownNCT03999697
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
Clinical Study of CD22 CAR T Cells in the Treatment of Patients With Relapsed or Refractory CD22 Positive B Cells With Acute Lymphoblastic Leukemia
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 3 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the efficacy and safety of CD22-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of recurrent or refractory CD22 positive B cell acute lymphoblastic leukemia (B-ALL)
Conditions
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Primary Cutaneous Follicle Centre Lymphoma
- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Mantle Cell Lymphoma
- Plasma Cell Neoplasm
- B Cell Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Autologous chimeric antigen receptor T cell transfusing agent targeting CD22 | The enrolled patients will receive autologous-derived CD22-targeted CAR-T cells in 1 day with 100% of the total expected dosage after receiving lymphodepleting chemotherapy |
Timeline
- Start date
- 2018-12-01
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
- First posted
- 2019-06-27
- Last updated
- 2019-06-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03999697. Inclusion in this directory is not an endorsement.